| Literature DB >> 17887661 |
Esther Martinborough1, Yixing Shen, Arjan van Oeveren, Yun Oliver Long, Thomas L S Lau, Keith B Marschke, William Y Chang, Francisco J López, Eric G Vajda, Peter J Rix, O Humberto Viveros, Andrés Negro-Vilar, Lin Zhi.
Abstract
The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17887661 DOI: 10.1021/jm070231h
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446